Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 12/2013

01.08.2013 | R&D Insight Report

Acotiamide: First Global Approval

verfasst von: Mary L. Nolan, Lesley J. Scott

Erschienen in: Drugs | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Acotiamide (Acofide®), an oral first-in-class prokinetic drug, is under global development by Zeria Pharmaceutical Co. Ltd and Astellas Pharma Inc. for the treatment of patients with functional dyspepsia. The drug modulates upper gastrointestinal motility to alleviate abdominal symptoms resulting from hypomotility and delayed gastric emptying. It exerts its activity in the stomach via muscarinic receptor inhibition, resulting in enhanced acetylcholine release and inhibition of acetylcholinesterase activity. Unlike other prokinetic drugs that are utilized in the management of functional dyspepsia, acotiamide shows little/no affinity for serotonin or dopamine D2 receptors. Acotiamide is the world’s first approved treatment for functional dyspepsia diagnosed by Rome III criteria, with its first approval occurring in Japan. Phase III trials in this patient population are in preparation in Europe, with phase II trials completed in the USA and Europe. This article summarizes the milestones in the development of acotiamide, leading to its first approval for use in patients with functional dyspepsia.
Literatur
1.
Tack J, Talley NJ. Functional dyspepsia—symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol. 2013;10(3):134–41.PubMedCrossRef
2.
Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10(3):187–94.PubMedCrossRef
3.
Karamanolis GP, Tack J. Current management of functional dyspepsia: impact of Rome III subdivision. Ann Gastroenterol. 2012;25(2):96–9.PubMedCentralPubMed
4.
Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012;36(1):3–15.PubMedCentralPubMedCrossRef
5.
Suzuki H, Hibi T. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia. Neurogastroenterol Motil. 2010;22(6):595–9.PubMedCrossRef
6.
Matsunaga Y, Tanaka T, Yoshinaga K, et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336(3):791–800.PubMedCrossRef
7.
Astellas P. Conclusion of co-development and co-marketing agreement on a functional dyspepsia agent Z-338/YM443 in Japan with Zeria. 2008. http://​www.​astellas.​com. Accessed 20 Jun 2013.
8.
Zeria Pharmaceutical Co. Ltd, Astellas Pharma Inc. Approval in Japan for treating functional dyspepsia with Acofide®. 2013. http://​www.​astellas.​com. Accessed 20 Jun 2013.
9.
10.
11.
12.
Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia—100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):618–25, e173.
13.
Tack JF, Stanghellini V, Holtmann G, et al. Efficacy and safety study of acotiamide (Z-338) in European patients with functional dyspepsia [abstract no. Tu1359]. Gastroenterology. 2011;140(5 Suppl.1):S805.
14.
Zeria Pharmaceutical Co. Ltd. To evaluate the efficacy and safety of acotiamide in subjects with functional dyspepsia [ClinicalTrials.gov identifier NCT00323817]. US National Institues of Health, ClinicalTrials.gov. 2011. http://​www.​clinicaltrials.​gov. Accessed 14 Jun 2013.
15.
Astellas Pharma Inc. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study of YM443 [Z 338, acotiamide] in subjects with functional dyspepsia [ClinicalTrials.gov identifier NCT00102310]. US National Institutes of Health, ClinicalTrials.gov. 2008. http://​www.​clinicaltrials.​gov. Accessed 12 Jun 2013.
16.
Talley NJ, et al. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial [abstract no. 1053]. Gastroenterology. 2008;134(4 Suppl.1):A157–8.
17.
Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821–8.PubMedCentralPubMedCrossRef
18.
Matsueda K, Hongo M, Ushijima S, et al. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261–8.PubMedCrossRef
19.
Zeria Pharmaceutical Co. Ltd, Yamanouchi Pharmaceutical Co. Ltd. Zeria and Yamanouchi sign letter of intent for development and marketing of the gastroprokinetic Z-338. 2002. http://​www.​yamanouchi.​com. Accessed 20 Jun 2013.
20.
21.
Yoshii K, Hirayama M, Nakamura T, et al. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach. J Pharm Sci. 2011;100(11):4965–73.PubMedCrossRef
22.
Doi Y, Murasaki O, Kaibara M, et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2004;505(1–3):31–5.
23.
Nagahama K, Matsunaga Y, Kawachi M, et al. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs. Neurogastroenterol Motil. 2012;24(6):566–74, e256.
24.
Kanemoto Y, Ishibashi H, Doi A, et al. An electrophysiological study of muscarinic and nicotinic receptors of rat paratracheal ganglion neurons and their inhibition by Z-338. Br J Pharmacol. 2002;135(6):1403–14.
25.
Nakajima T, Nawata H, Ito Y. Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J Smooth Muscle Res. 2000;36(2):69–81.PubMedCrossRef
26.
Kawachi M, Matsunaga Y, Tanaka T, et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmacol. 2011;666(1–3):218–25.PubMedCrossRef
27.
Ogishima M, Kaibara M, Ueki S, et al. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther. 2000;294(1):33–7.PubMed
28.
Morita H, Abe K, Ito Y, et al. Possible involvement of M5 muscarinic receptor in the enhancing actions of the novel gastroprokinetic agent Z-338 on nifedipine-sensitive voltage-dependent Ca2+ currents in guinea pig stomach. Jpn J Pharmacol. 2002;89(4):356–65.PubMedCrossRef
29.
Akaike H, Jang II-S, Hori N, et al. Effects of Z-338, a novel gastroprokinetic agent, on the actions of excitatory and inhibitory neurotransmitters on neurons in area postrema. J Smooth Muscle Res. 2010;46(1):31–47.PubMedCrossRef
30.
Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil. 2008;20(9):1051–9.PubMedCrossRef
31.
Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil. 2009;21(3):272–80.PubMedCrossRef
32.
Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540–5, e250–1.
33.
Adam B, Liebregis T, Zschau NB, et al. Z-338 improves meal-induced symptoms in functional dyspepsia; a double-blind, randomized, placebo controlled crossover study [abstract no. T1266]. Gastroenterol. 2009;136(5 Suppl.1):A535.
34.
Zeria Pharmaceutical Co. Ltd. The effects of Z-338 in subjects with and without functional dyspepsia [ClinicalTrials.gov identifier NCT00298194]. US National Institues of Health, ClinicalTrials.gov. 2009. http://​www.​clinicaltrials.​gov. Accessed 25 Jun 2013.
35.
Astellas Pharma Inc. A phase I, randomized, double-blind, placebo- and active-controlled, crossover study to evaluate the effect of repeat oral doses of YM443 on cardiac repolarization in healthy male and female adult subjects [ClinicalTrials.gov identifier NCT00850746] US National Institutes of Health, ClinicalTrials.gov. 2010. http://​www.​clinicaltrials.​gov. Accessed 18 Jun 2013.
36.
Oliver SD, Ward C, Ward J, et al. Z-338: phase I, single and multiple oral dose, safety, tolerability and pharmacokinetic studies in healthy male subjects [abstract no. 948 plus poster]. In: 7th world conference on clinical pharmacology and therapeutics (CPT) and the 4th congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), 16–20 July 2000, Florence.
37.
Furuta S, Kamada E, Omata T, et al. Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Eur J Pharmacol. 2004;497(2):223–31.PubMedCrossRef
38.
Matsueda K, Hongo M, Tack JF, et al. Efficacy of acotiamide (Z-338) in patients with postprandial distress syndrome or overlap of epigastric pain syndrome and postprandial distress syndrome in functional dyspepsia [abstract no. Tu1357]. Gastroenterology. 2011;140(5 Suppl. 1):S805.
Metadaten
Titel
Acotiamide: First Global Approval
verfasst von
Mary L. Nolan
Lesley J. Scott
Publikationsdatum
01.08.2013
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 12/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0100-9

Weitere Artikel der Ausgabe 12/2013

Drugs 12/2013 Zur Ausgabe

Adis Drug Evaluation

Sumatriptan/Naproxen Sodium: A Review of Its Use in Adult Patients with Migraine

Adis Drug Evaluation

Zonisamide: A Review of Its Use in the Management of Adults with Partial Seizures

Review Article

Treatment of Opioid-Induced Constipation: Focus on the Peripheral μ-Opioid Receptor Antagonist Methylnaltrexone

Adis Drug Evaluation

Recombinant Trivalent Influenza Vaccine (Flublok®): A Review of Its Use in the Prevention of Seasonal Influenza in Adults

Systematic Review

Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review

Therapy in Practice

Management of Neurogenic Orthostatic Hypotension in Patients with Autonomic Failure